Loading…

Research Domain - Smoking Cessation, Harm Reduction and Biomarkers

Select Protocol ID

Shiffman, S., et al. Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers. J Consult Clin Psych, 2006.
#330101

Heaviness of Smoking Index (HSI)
#330201

Caraballo RS, et al. Quit Methods Used by US Adult Cigarette Smokers, 2014-2016. Prev Chronic Dis, 2017.
#330301

National Health and Nutrition Examination Survey (NHANES) Cotinine and Hydroxycotinine Analysis
#330401

Population Assessment of Tobacco and Health (PATH) Study, PATH Wave 3 Adult Annotated Instrument, 2018
#330501

Population Assessment of Tobacco and Health (PATH) Study, PATH Waves 1 and 3 Adult Annotated Instrument, 2016-2018
#330503

Population Assessment of Tobacco and Health (PATH) Study, PATH Wave 1 Adult Annotated Instrument, 2016
#330502

Population Assessment of Tobacco and Health (PATH) Study, PATH Wave 1 Adult Annotated Instrument, 2016 
#330504

Population Assessment of Tobacco and Health (PATH) Study, PATH Waves 1 and 3 Adult Annotated Instrument, 2016-2018
#330505

Smoking Self-Efficacy Questionnaire (SEQ-12)
#330801

Partner Interaction Questionnaire (PIQ-20)
#330901
Release Date:

February 23, 2021

Scope of Domain:
Scope Elements Final Protocols To Toolkit (13)
Biomarkers Nicotine Metabolite Ratio – Serum and Saliva
Mechanism of Cessation/Outcomes Cessation Milestones: Abstinence from Cigarettes
Mediators of Treatment Effects Perception of Tobacco Product Risk – Cigarettes*
Mediators of Treatment Effects Perception of Tobacco Product Risk – Cigars*
Mediators of Treatment Effects Perception of Tobacco Product Risk – E-Cigarettes*
Mediators of Treatment Effects Perception of Tobacco Product Risk – Pipe Tobacco*
Mediators of Treatment Effects Perception of Tobacco Product Risk – Smokeless Tobacco*
Risk Factors Heaviness of Smoking - Cigarettes
Risk Factors Self-Efficacy for Not Smoking
Risk Factors Social Support for Quitting Smoking
Treatment Adherence to Smoking Cessation Medication – Self-Report
Treatment Methods of Quitting Smoking Cigarettes – Adults
*Perception of Tobacco Product Risk assesses both Mediators of Treatment Effects and Risk Factors.
Working Group Roster:

WG Members:

Laura J. Bierut, MD, Co-Chair
Washington University in St. Louis
St. Louis, MO
Gary E. Swan, PhD, Co-Chair
Stanford University School of Medicine
Stanford, CA
Neal L. Benowitz, MD
University of California, San Francisco
San Francisco, CA
K. Michael Cummings, PhD, MPH
Medical University of South Carolina
Charleston, SC
Robin J. Mermelstein, PhD
University of Illinois at Chicago
Institute for Health Research and Policy
Chicago, IL
Megan E. Piper, PhD
University of Wisconsin, Madison
Madison, WI
Scott I. Vrieze, PhD
University of Minnesota
Minneapolis, MN
Theodore Wagener, PhD
The Ohio State University
Columbus, OH

SC Liaison, WG Manager and WG Supervisor:

Tabitha P. Hendershot, BA, SC Liaison
RTI International
Washington, DC
Cataia Ives, MS, WG Manager
RTI International
Research Triangle Park, NC
Mark Nelms, PhD, WG Supervisor
RTI International
Research Triangle Park, NC
Smoking Cessation, Harm Reduction and Biomarkers Supplemental Information includes:

There is no supplemental information for this domain.

Additional Information for Smoking Cessation, Harm Reduction and Biomarkers Measures:

There is no additional information for this domain.

Protocol Name Status DCW DD DD Mapping